Bruce Keyt - 06 Sep 2022 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Chief Scientific Officer
Signature
/s/ Misbah Tahir, by power of attorney
Issuer symbol
IGMS
Transactions as of
06 Sep 2022
Net transactions value
-$460,290
Form type
4
Filing time
08 Sep 2022, 17:34:44 UTC
Previous filing
22 Aug 2022
Next filing
06 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Options Exercise $4,650 +5,000 +13% $0.9300* 44,489 06 Sep 2022 Direct F1
transaction IGMS Common Stock Sale $95,321 -5,000 -11% $19.06 39,489 06 Sep 2022 Direct F1, F2
transaction IGMS Common Stock Options Exercise $9,300 +10,000 +25% $0.9300* 49,489 07 Sep 2022 Direct F1
transaction IGMS Common Stock Sale $190,392 -10,000 -20% $19.04 39,489 07 Sep 2022 Direct F1, F3
transaction IGMS Common Stock Options Exercise $9,300 +10,000 +25% $0.9300* 49,489 08 Sep 2022 Direct F1
transaction IGMS Common Stock Sale $142,196 -7,265 -15% $19.57 42,224 08 Sep 2022 Direct F1, F4
transaction IGMS Common Stock Sale $55,632 -2,735 -6.5% $20.34 39,489 08 Sep 2022 Direct F1, F5
holding IGMS Common Stock 1,013 06 Sep 2022 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Stock Option (right to buy) Options Exercise $0 -5,000 -4.6% $0.000000 103,756 06 Sep 2022 Common Stock 5,000 $0.9300 Direct F1, F7
transaction IGMS Stock Option (right to buy) Options Exercise $0 -10,000 -9.6% $0.000000 93,756 07 Sep 2022 Common Stock 10,000 $0.9300 Direct F1, F7
transaction IGMS Stock Option (right to buy) Options Exercise $0 -10,000 -11% $0.000000 83,756 08 Sep 2022 Common Stock 10,000 $0.9300 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $18.75 to $19.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $19.00 to $19.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $19.25 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $20.25 to $20.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 The shares are held directly by the reporting person's spouse.
F7 The shares subject to the option are vested and exercisable as of the date hereof.